- Home
- DRRX
DRRX
DURECT Corporation
as 08-28-2025 4:00pm EST
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | CUPERTINO |
| Market Cap: | 59.3M | IPO Year: | 2000 |
| Target Price: | N/A | AVG Volume (30 days): | 557.2K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.48 - $2.64 | Next Earning Date: | 08-12-2025 |
| Revenue: | $1,657,000 | Revenue Growth: | -21.58% |
| Revenue Growth (this year): | -50.02% | Revenue Growth (next year): | 673.00% |
Stock Insider Trading Activity of DURECT Corporation (DRRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ASEN R SCOTT | DRRX | N/A | Aug 22 '25 | Buy | $1.92 | 5,917 | $11,357.09 | 2,672,529 | |
| ASEN R SCOTT | DRRX | N/A | Aug 21 '25 | Buy | $1.90 | 116,612 | $221,306.25 | 2,672,529 | |
| ASEN R SCOTT | DRRX | N/A | Aug 20 '25 | Buy | $1.89 | 87,608 | $165,360.10 | 2,672,529 |
Latest DURECT Corporation News
DRRX Breaking Stock News: Dive into DRRX Ticker-Specific Updates for Smart Investing
Associated Press Finance
3 months ago
Durect: Q1 Earnings Snapshot
PR Newswire
4 months ago
DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
Simply Wall St.
5 months ago
Here's Why We're A Bit Worried About DURECT's (NASDAQ:DRRX) Cash Burn Situation
Thomson Reuters StreetEvents
5 months ago
Q4 2024 DURECT Corp Earnings Call
GuruFocus.com
5 months ago
Durect Corp (DRRX) Q4 2024 Earnings Call Highlights: Strategic Focus Amid Financial Challenges
Zacks
5 months ago
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates
Associated Press Finance
5 months ago
Durect: Q4 Earnings Snapshot
PR Newswire
5 months ago
DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Compare DRRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DRRX DURECT Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.